A meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists for acute chemotherapy-induced emesis

Jordan, Karin; Hinke, Axel; Grothey, Axel; Voigt, Wieland; Arnold, Dirk; Wolf, Hans Heinrich; Schmoll, Hans Joachim

doi:10.1007/s00520-006-0186-7

Cited by 84 publications

(51 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As such, the NCCN guidelines recommend ondansetron at a dose of 16 -24 mg orally and 8 -12 mg (maximum, 32 mg) i.v., whereas the MASCC and ASCO guidelines recommend ondansetron at a dose of 24 mg orally (MASCC, 16 mg orally for moderately emetogenic chemotherapy) and 8 mg or 0.15 mg/kg i.v. In a recently published meta-analysis comparing low-dose ondansetron (8 mg) with high-dose ondansetron (24 or 32 mg), in a subanalysis in cisplatinbased chemotherapy, high-dose ondansetron appeared to be more effective (p ϭ .012) [12].…”

Section: Ondansetronmentioning

confidence: 99%

See 1 more Smart Citation

Guidelines for Antiemetic Treatment of Chemotherapy-Induced Nausea and Vomiting: Past, Present, and Future Recommendations

2007

View full text Add to dashboard Cite

After completing this course, the reader will be able to:1. Explain the optimal antiemetic prophylaxis for patients receiving chemotherapy in regard to the emetogenic potential of the therapy.2. Describe the difference between acute and delayed emesis.3. Discuss the properties and optimal use of the different antiemetic drugs.Access and take the CME test online and receive 1 AMA PRA Category 1 Credit ™ at CME.TheOncologist.com CME CME ABSTRACT

show abstract

Section: Ondansetronmentioning

confidence: 99%

“…For a better understanding, the results of the three available randomized studies with palonosetron in the acute phase are outlined in Table 4. In a recently published meta-analysis, palonosetron was not included because only two studies were fully published at that time [12][13][14].…”

Section: Palonosetronmentioning

confidence: 99%

Guidelines for Antiemetic Treatment of Chemotherapy-Induced Nausea and Vomiting: Past, Present, and Future Recommendations

2007

View full text Add to dashboard Cite

show abstract

“…The present study investigated CINV during MEC treatment. MEC-induced vomiting in the acute phase is well controlled by 5-HT3 receptor antagonists (Perez et al, 1998;Jordan et al, 2007). However, delayed vomiting and nausea throughout the treatment period are still not well controlled during MEC, causing negative attitudes towards treatment and hindering the continuation of chemotherapy.…”

Section: Discussionmentioning

confidence: 99%

Efficacy of Aprepitant in Patients with Advanced or Recurrent Lung Cancer Receiving Moderately Emetogenic Chemotherapy

Uchino

Hirano

Tashiro

et al. 2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

“…7,8 According to the American Society of Clinical Oncology (ASCO) guidelines for antiemetic management in cancer patients, the standard preventive treatment for CINV is based on selective 5-HT3-receptor antagonists (5HT3AR), corticosteroids and neurokinin-1-receptor antagonists (NK1AR), combined to match the intensity of chemotherapy-induced vomiting. [9][10][11][12][13][14] Despite the use of such therapy, approximately 50% of patients still present CINV. 15 However, treatment with these three drugs has a high cost and some of them are unavailable in centers where healthcare funding is provided by the government.…”

Section: Introductionmentioning

confidence: 99%

Carbamazepine for prevention of chemotherapy-induced nausea and vomiting: a pilot study

et al. 2014

View full text Add to dashboard Cite

CONTEXT AND OBJECTIVE: Nausea and vomiting are major inconveniences for patients undergoing chemotherapy. Despite standard preventive treatment, chemotherapy-induced nausea and vomiting (CINV) still occurs in approximately 50% of these patients. In an attempt to optimize this treatment, we evaluated the possible effects of carbamazepine for prevention of CINV. DESIGN AND LOCATION:Prospective nonrandomized open-label phase II study carried out at a Brazilian public oncology service. METHODS:Patients allocated for their first cycle of highly emetogenic chemotherapy were continuously recruited. In addition to standard antiemetic protocol that was made available, they received carbamazepine orally, with staggered doses, from the third day before until the fifth day after chemotherapy. Considering the sparseness of evidence about the efficacy of anticonvulsants for CINV prevention, we used Simon's two-stage design, in which 43 patients should be included unless overall complete prevention was not achieved in 9 out of the first 15 entries. The Functional Living Index-Emesis questionnaire was used to measure the impact on quality of life. RESULTS: None of the ten patients (0%) presented overall complete prevention. In three cases, carbamazepine therapy was withdrawn because of somnolence and vomiting before chemotherapy. Seven were able to take the medication for the entire period and none were responsive, so the study was closed. There was no impact on the patients' quality of life. CONCLUSION: Carbamazepine was not effective for prevention of CINV and also had a deleterious sideeffect profile in this population. CLINICAL TRIAL REGISTRATION: NCT01581918.RESUMO CONTEXTO E OBJETIVO: Náusea e vômito são inconvenientes importantes para pacientes submetidos a quimioterapia. A despeito do tratamento preventivo padrão, náuseas e vômitos induzidos por quimioterapia (NVIQ) ocorrem em aproximadamente 50% dos pacientes. Na tentativa de otimizar este tratamento, avaliamos os possíveis efeitos da carbamazepina na prevenção de náuseas e vômitos induzidos por quimioterapia. TIPO DE ESTUDO E LOCAL: Estudo fase II, prospectivo, não randomizado, aberto, realizado em um serviço público brasileiro de oncologia. MÉTODOS: Recrutaram-se continuamente pacientes alocados para o primeiro ciclo de quimioterapia altamente emetogênica. Além do protocolo anti-emético padrão disponibilizado, os pacientes receberam carbamazepina, por via oral, em doses escalonadas, a partir do terceiro dia anterior até o quinto dia após a quimioterapia. Dada a escassa evidência de eficácia dos anticonvulsivantes na prevenção de NVIQ, adotamos o desenho de Simon em duas fases, que deveria incluir 43 pacientes a não ser que prevenção completa global não fosse alcançada em 9 dos primeiros 15 participantes. O questionário "Functional Living Index-Emesis" foi usado para avaliar o impacto na qualidade da vida. RESULTADOS: Nenhum dos 10 pacientes (0%) apresentou prevenção completa global. Três tiveram a carbamazepina suspensa por sonolência e vômito antes da quimio...

show abstract

A meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists for acute chemotherapy-induced emesis

Abstract: Efficacy of 5-HT(3)RAs for preventing CINV following cisplatin- and non-cisplatin-based chemotherapy is comparable, with the exception of granisetron vs tropisetron. Some differences were noted in dosing subanalyses.

Cited by 84 publications

References 54 publications

Guidelines for Antiemetic Treatment of Chemotherapy-Induced Nausea and Vomiting: Past, Present, and Future Recommendations

Guidelines for Antiemetic Treatment of Chemotherapy-Induced Nausea and Vomiting: Past, Present, and Future Recommendations

Efficacy of Aprepitant in Patients with Advanced or Recurrent Lung Cancer Receiving Moderately Emetogenic Chemotherapy

Carbamazepine for prevention of chemotherapy-induced nausea and vomiting: a pilot study

Contact Info

Product

Resources

About